The Translational Oncology Program consists of 39 participating Members, representing total peer-reviewed funding for nearly $7.2 Million in annual direct costs ($10.5 Million in total costs). During the last two years, its Members produced 155 cancer-relevant publications, 32% of which were intra- and inter-programmatic collaborations. This program consists of members who conduct or who have active participation in bed-to-bench-to-bed research that integrates basic laboratory studies with clinical investigation. Such translational research is essential for the development of improved diagnostic, disease- monitoring strategies, and treatments for patients with cancer. Accordingly, the achievements of the Program have been to: (1) make new contributions to the identification of molecular signatures characteristic of cancer cells, such as disorderly CD44 and telomerase gene expression; (2) Introduce novel treatments, such as CD40 ligand gene therapy for CLL and bispecific antibody therapy for leukemia, and; (3) develop clinical trials and clinical correlated laboratory studies that test the value of institutional discoveries, such as new methods of combination biochemotherapy for melanoma, and (4) advance national cooperative group protocols. To achieve these goals, the Translational Oncology program has developed Specialized Cancer Units in the following fields: Breast Cancer, Gastrointestinal Cancer, Leukemia/Lymphoma, Melanoma, Cancer Pain Relief, Stem Cell Transplant and Urologic Cancer and is dedicated to strengthening multi- disciplinary research and clinical care in these areas.
| Murzin, Vyacheslav L; Woods, Kaley; Moiseenko, Vitali et al. (2018) 4? plan optimization for cortical-sparing brain radiotherapy. Radiother Oncol 127:128-135 |
| Norton, Jeffrey A; Kim, Teresa; Kim, Joseph et al. (2018) SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 22:32-42 |
| Ikeda, Sadakatsu; Tsigelny, Igor F; Skjevik, Åge A et al. (2018) Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 23:586-593 |
| Buckley, Alexandra R; Ideker, Trey; Carter, Hannah et al. (2018) Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Med 10:69 |
| Parish, Austin J; Nguyen, Vi; Goodman, Aaron M et al. (2018) GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 124:4080-4089 |
| Xu, Selene; Thompson, Wesley; Ancoli-Israel, Sonia et al. (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships. Psychooncology 27:802-809 |
| Tao, Li; Schwab, Richard B; San Miguel, Yazmin et al. (2018) Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California. Cancer Epidemiol Biomarkers Prev : |
| Sagredo, Eduardo A; Blanco, Alejandro; Sagredo, Alfredo I et al. (2018) ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biol Res 51:36 |
| Ramdani, Ghania; Schall, Nadine; Kalyanaraman, Hema et al. (2018) cGMP-dependent protein kinase-2 regulates bone mass and prevents diabetic bone loss. J Endocrinol 238:203-219 |
| Nguyen, Vi; Marmor, Rebecca A; Ramamoorthy, Sonia L et al. (2018) The Use of Solicited Publishing by Academic Surgeons. Surgery 164:212-218 |
Showing the most recent 10 out of 862 publications
